Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 10:18 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Community-acquired Pneumonia Clear all
Completed Not applicable Interventional Results available

Improving CarE for Community Acquired Pneumonia 1

NCT03760419
View directory record Official record
Conditions
Pneumonia Childhood
Interventions
Clinical Decision Support
Behavioral
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
6 Months to 18 Years
Enrollment
1,027 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 7, 2022 · Synced Jun 10, 2026, 10:18 PM EDT
Completed Not applicable Interventional

Neuromuscular Electrical Stimulation in COPD/Community Acquired Pneumonia

NCT05452226
View directory record Official record
Conditions
Community-acquired Pneumonia, COPD Exacerbation Acute
Interventions
neuromuscular electrical stimulation (NMES)
Device
Lead sponsor
University of Vermont
Other
Eligibility
50 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Jun 10, 2026, 10:18 PM EDT
Completed Phase 3 Interventional

New Antibiotic to Treat Patients With Community-acquired Pneumonia Due to a Specific Bacteria (S. Pneumoniae Pneumonia)

NCT00035269
View directory record Official record
Conditions
Pneumonia, Pneumococcal, Community Acquired Infections, Gram-positive Bacterial Infections
Interventions
Antibiotic
Drug
Lead sponsor
Pfizer
Industry
Eligibility
13 Years and older
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
34
States / cities
Los Angeles, California • Jacksonville, Florida • Naples, Florida + 29 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2011 · Synced Jun 10, 2026, 10:18 PM EDT
Recruiting Phase 4 Interventional

Azithromycin Versus Doxycycline in Hospitalized Adult Patients With Community Acquired Pneumonia Treated With Beta-lactams

NCT07164131
View directory record Official record
Conditions
Community-acquired Pneumonia
Interventions
Doxycycline, Azithromycin
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
1,120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
5
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Mankato, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2025 · Synced Jun 10, 2026, 10:18 PM EDT
Completed Phase 1 Interventional Results available

Study to Evaluate the PK of PO Omadacycline in Adults With Community-Acquired Bacterial Pneumonia

NCT04160260
View directory record Official record
Conditions
Community-acquired Pneumonia
Interventions
Omadacycline
Drug
Lead sponsor
Paratek Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
13
States / cities
Birmingham, Alabama • San Diego, California • Clearwater, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2021 · Synced Jun 10, 2026, 10:18 PM EDT
Completed Phase 3 Interventional Results available

Study to Compare Lefamulin to Moxifloxacin for the Treatment of Adults With Pneumonia

NCT02813694
View directory record Official record
Conditions
Community Acquired Pneumonia
Interventions
lefamulin, Moxifloxacin
Drug
Lead sponsor
Nabriva Therapeutics AG
Industry
Eligibility
18 Years and older
Enrollment
738 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
25
States / cities
Beverly Hills, California • Fresno, California • Northridge, California + 20 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2019 · Synced Jun 10, 2026, 10:18 PM EDT
Not yet recruiting Not applicable Interventional

Ketogenic Approach to Restore Muscle in Older Patients With Community-Acquired Pneumonia - KARMA-P Trial

NCT07308483
View directory record Official record
Conditions
Pneumonia
Interventions
Ketogenic feeding, Standard feeding
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
55 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Dec 28, 2025 · Synced Jun 10, 2026, 10:18 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Clinical Indicators of Radiographic Findings in Patients With Suspected Community-Acquired Pneumonia

NCT00118651
View directory record Official record
Conditions
Pneumonia
Interventions
Not listed
Lead sponsor
David Grant U.S. Air Force Medical Center
Federal
Eligibility
18 Years and older
Enrollment
350 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2005
U.S. locations
1
States / cities
Travis Air Force Base, California
Source: ClinicalTrials.gov public record
Updated Apr 16, 2020 · Synced Jun 10, 2026, 10:18 PM EDT
Completed Phase 3 Interventional

Tifacogin for the Treatment of Patients With Severe Community-Acquired Pneumonia

NCT00084071
View directory record Official record
Conditions
Pneumonia
Interventions
Tifacogin
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
Not listed
Enrollment
2,136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
51
States / cities
Mobile, Alabama • Loma Linda, California • Los Angeles, California + 48 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2020 · Synced Jun 10, 2026, 10:18 PM EDT
Terminated Phase 4 Interventional

KEYS: Study Comparing Clinical Health Outcomes of Telithromycin Versus Azithromycin in Outpatients With Community-acquired Lower Respiratory Tract Infections

NCT00132951
View directory record Official record
Conditions
Respiratory Tract Infections, Chronic Bronchitis, Pneumonia
Interventions
Telithromycin, Azithromycin
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 35 Years
Enrollment
2,051 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 26, 2009 · Synced Jun 10, 2026, 10:18 PM EDT
Completed Not applicable Interventional Results available

Swab Testing to Optimize Pneumonia Treatment With Empiric Vancomycin

NCT06272994
View directory record Official record
Conditions
Community-acquired Pneumonia
Interventions
MRSA Nasal Swab PCR
Diagnostic Test
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
277 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced Jun 10, 2026, 10:18 PM EDT
Completed Not applicable Interventional

Using Probability of Community-Acquired Pneumonia to Tailor Antimicrobials Among Inpatients

NCT05976581
View directory record Official record
Conditions
Pneumonia, Pneumonia, Viral, Pneumonia, Bacterial
Interventions
Electronic alert, Structured communication of test results
Behavioral
Lead sponsor
Jonathan Baghdadi
Other
Eligibility
18 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
2
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Jun 10, 2026, 10:18 PM EDT
Completed Phase 3 Interventional

A Multicenter, Randomized, Double-Blind, Double-Dummy Trial of Azithromycin SR Compared With Clarithromycin Extended Release for the Treatment of Pneumonia in Adult Patients

NCT00643227
View directory record Official record
Conditions
Pneumonia
Interventions
clarithromycin extended release (ER), azithromycin SR
Drug
Lead sponsor
Pfizer
Industry
Eligibility
16 Years and older
Enrollment
504 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
36
States / cities
Birmingham, Alabama • Haleyville, Alabama • Montgomery, Alabama + 24 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2008 · Synced Jun 10, 2026, 10:18 PM EDT
Completed Phase 3 Interventional Results available

Omadacycline vs Moxifloxacin for the Treatment of CABP (EudraCT #2013-004071-13)

NCT02531438
View directory record Official record
Conditions
Bacterial Pneumonia, Community-Acquired Infections
Interventions
Omadacycline, Moxifloxacin
Drug
Lead sponsor
Paratek Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
774 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
12
States / cities
Birmingham, Alabama • Mobile, Alabama • Laguna Hills, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2019 · Synced Jun 10, 2026, 10:18 PM EDT
Recruiting Phase 3 Interventional

Efficacy and Safety of Trimodulin (BT588) in Subjects With Severe Community-acquired Pneumonia (sCAP)

NCT05722938
View directory record Official record
Conditions
Community-acquired Pneumonia
Interventions
Trimodulin, Placebo (human albumin 1%)
Drug
Lead sponsor
Biotest
Industry
Eligibility
18 Years and older
Enrollment
590 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
19
States / cities
Mobile, Alabama • Fresno, California • Sacramento, California + 16 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced Jun 10, 2026, 10:18 PM EDT
Recruiting Phase 3 Interventional

Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia

NCT02735707
View directory record Official record
Conditions
Community-acquired Pneumonia, Influenza, COVID-19
Interventions
Ceftriaxone, Moxifloxacin or Levofloxacin, Piperacillin-tazobactam, Ceftaroline, Amoxicillin-clavulanate, Standard course macrolide, Extended course macrolide, No systemic corticosteroid, Fixed-duration Hydrocortisone, Shock-dependent hydrocortisone, Fixed-duration higher dose Hydrocortisone, No antiviral agent for influenza, Five-days oseltamivir, Ten-days oseltamivir, No antiviral agent for COVID-19, Lopinavir / Ritonavir, Hydroxychloroquine, Hydroxychloroquine + lopinavir/ritonavir, Ivermectin, No immune modulation for COVID-19, Interferon beta-1a, Anakinra, Tocilizumab, Sarilumab, Local standard venous thromboprophylaxis, Therapeutic dose anticoagulation, Conventional low dose thromboprophylaxis, Intermediate dose thromboprophylaxis, Continuation of therapeutic dose anticoagulation, No immunoglobulin, Convalescent plasma, Delayed administration of convalescent plasma, No vitamin C, Vitamin C, No antiplatelet, Aspirin, P2Y12 inhibitor, No simvastatin, Simvastatin, Eritoran, Apremilast, Clinician-preferred mechanical ventilation strategy, Protocolised mechanical ventilation strategy, No renin-angiotensin system inhibitor, Angiotensin converting enzyme inhibitor, Angiotensin Receptor Blockers, ARB + DMX-200, No cysteamine, Cysteamine, Fixed-duration dexamethasone, Baloxavir Marboxil, Five-days oseltamivir + baloxavir marboxil, Ten-days oseltamivir + baloxavir marboxil, No endothelial modulator, Imatinib, No Immune Modulator for Influenza, Baricitinib, Nirmatrelvir/ritonavir, Remdesivir, Nirmatrelvir/ritonavir + remdesivir
Drug · Other · Biological + 1 more
Lead sponsor
UMC Utrecht
Other
Eligibility
18 Years and older
Enrollment
20,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
11
States / cities
Jacksonville, Florida • Augusta, Georgia • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2024 · Synced Jun 10, 2026, 10:18 PM EDT
Completed Phase 3 Interventional Results available

Study Comparing the Safety and Efficacy of Cethromycin to Clarithromycin for the Treatment of Community-Acquired Pneumonia

NCT00336544
View directory record Official record
Conditions
Pneumonia
Interventions
Cethromycin, Clarithromycin
Drug
Lead sponsor
Advanced Life Sciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
522 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
13
States / cities
Woodridge, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 25, 2010 · Synced Jun 10, 2026, 10:18 PM EDT
Completed No phase listed Observational

An Observational Study to Assess the Prevalence and Outcomes of Primary Pulmonary Coccidioidomycosis in Persons Aged > / = 14 Years Presenting With Community Acquired Pneumonia (CAP) in Endemic Areas (SAnds-PPC)

NCT03908632
View directory record Official record
Conditions
Coccidioidomycosis, Pneumonia
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
14 Years to 99 Years
Enrollment
651 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
6
States / cities
Phoenix, Arizona • Tucson, Arizona • Bakersfield, California + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2024 · Synced Jun 10, 2026, 10:18 PM EDT
Completed Not applicable Interventional Results available

Improving CarE for Community Acquired Pneumonia 1 (ICE-CAP2)

NCT06033079
View directory record Official record
Conditions
Pneumonia Childhood
Interventions
Clinical Decision Support
Behavioral
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
6 Months to 18 Years
Enrollment
536 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 4, 2023 · Synced Jun 10, 2026, 10:18 PM EDT
Withdrawn Not applicable Interventional

Microbiology Testing With the Aim Of Directed Antimicrobial Therapy For CAP

NCT01662258
View directory record Official record
Conditions
Community-acquired Pneumonia
Interventions
Point-of-Care diagnostic laboratory test
Device
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
5
States / cities
Louisville, Kentucky • Baltimore, Maryland • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2016 · Synced Jun 10, 2026, 10:18 PM EDT
Completed No phase listed Observational

Use Of Procalcitonin Level For Guidance of The Treatment of Suspected Community Acquired Pneumonia

NCT00914550
View directory record Official record
Conditions
Pneumonia, Radiographic Lung Infiltrates
Interventions
Procalcitonin level, caregiver informed
Other
Lead sponsor
Winthrop University Hospital
Other
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Mineola, New York
Source: ClinicalTrials.gov public record
Updated Dec 14, 2014 · Synced Jun 10, 2026, 10:18 PM EDT
Completed Phase 2 Interventional

Efficacy and Safety Study of Oral CEM-101 Compared to Oral Levofloxacin in Treatment of Patients With Community-Acquired Bacterial Pneumonia

NCT01168713
View directory record Official record
Conditions
Community-Acquired Bacterial Pneumonia
Interventions
Levofloxacin, CEM-101
Drug
Lead sponsor
Melinta Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
45
States / cities
Birmingham, Alabama • Flagstaff, Arizona • Bell Gardens, California + 41 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2017 · Synced Jun 10, 2026, 10:18 PM EDT
Withdrawn No phase listed Observational

Clinical Pediatric Pneumonia Score in Critically Ill Children

NCT02139384
View directory record Official record
Conditions
Community Acquired Pneumonia
Interventions
Not listed
Lead sponsor
Loma Linda University
Other
Eligibility
1 Day to 21 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Apr 24, 2017 · Synced Jun 10, 2026, 10:18 PM EDT
Completed Phase 4 Interventional Results available

Evaluation of Ceftaroline Fosamil Versus a Comparator in Adult Subjects With Community-acquired Bacterial Pneumonia (CABP) With Risk for Methicillin-resistant Staphylococcus Aureus

NCT01645735
View directory record Official record
Conditions
Infections
Interventions
Ceftaroline fosamil, Ceftriaxone plus vancomycin
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
13
States / cities
Phoenix, Arizona • Sylmar, California • DeLand, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2016 · Synced Jun 10, 2026, 10:18 PM EDT